New antifungal treatments for Talaromycosis in HIV patients
Official title: Liposomal Amphotericin B and Flucytosine Antifungal Strategies for Talaromycosis (LAmB-FAST)
Funded at Duke University · NIH-11011653 · Data updated 2026-11-12
This study is looking at new treatment options for Talaromycosis, a serious fungal infection that affects people with advanced HIV, especially in Southeast Asia, to see if a combination of two medicines can help patients get better faster and with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | August 16, 2024 |
| Project end | June 30, 2031 |
| Funding year | 2024 |
| Award (this year) | $1,326,630 |
| NIH project number | 1R01AI181764-01A1 |
| Project ID | NIH-11011653 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Talaromycosis, particularly those with advanced HIV disease.
✕Less likely to help
Patients who do not have Talaromycosis or are not affected by HIV may not benefit from this research.
What this research studies
This research focuses on improving treatment options for Talaromycosis, a serious fungal infection that affects patients with advanced HIV, particularly in Southeast Asia. The study aims to evaluate the effectiveness and safety of using liposomal amphotericin B and flucytosine as alternative therapies, which may offer shorter treatment durations and reduced toxicity compared to traditional methods. By leveraging recent advancements in antifungal therapies, the research seeks to enhance patient outcomes and survival rates. Patients participating in this research may receive innovative treatment regimens that could significantly improve their health.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective antifungal treatments for patients suffering from Talaromycosis.
How similar studies have gone: Previous research has shown success with similar approaches in treating other AIDS-associated fungal infections, indicating potential for this novel treatment strategy.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Le, Thuy — Duke University
- Study coordinator: Le, Thuy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.